The Medicare Bridge program glp1 is now available to eligible Medicare beneficiaries, giving qualifying adults access to certain GLP-1 medications for weight management at a $50 monthly copayment. The federal demonstration began July 1, 2026, and current rules keep it available through December 31, 2027.
The program comes from the Centers for Medicare & Medicaid Services (CMS) and targets a specific group of Medicare beneficiaries with qualifying prescription drug coverage. It does not create universal Medicare coverage for every GLP-1 medication or every person seeking weight-loss treatment.
Instead, CMS established specific eligibility standards covering Medicare enrollment, prescription drug coverage, BMI, qualifying medical conditions, medication use and prior authorization.
The program has also become an important part of the federal government’s broader approach to GLP-1 access. CMS is using the demonstration to gather information about medication use and costs while determining how future Medicare policies could address these drugs.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge is a CMS demonstration designed to provide qualifying Medicare Part D beneficiaries with access to selected GLP-1 medications for weight management.
The program operates differently from ordinary Medicare Part D coverage.
Eligible prescriptions are processed through a separate structure, and beneficiaries who meet the program requirements pay $50 for a monthly supply of an eligible medication.
The program launched on July 1, 2026. CMS has set December 31, 2027, as the current end date.
That date matters because the Bridge is a demonstration rather than a permanent Medicare benefit. Its current operation does not guarantee that the same coverage will continue after 2027.
The program is available throughout the United States and U.S. territories for beneficiaries who satisfy the applicable rules.
Why Medicare Created the Bridge
GLP-1 medications have become increasingly important in weight-management care. Medicare coverage rules, however, have historically treated weight-loss use differently from several other approved medical indications.
CMS created the Bridge to establish a specific access route for qualifying Medicare beneficiaries who need GLP-1 treatment for weight management.
The demonstration also allows the federal government to collect information about utilization, prescription patterns and program administration.
The approach separates the Bridge from the standard Part D benefit.
A beneficiary therefore should not assume that an existing Medicare prescription plan automatically covers a GLP-1 under the Bridge.
The medication, medical purpose and beneficiary’s circumstances all matter.
Who Can Use the Medicare GLP-1 Bridge?
Eligibility depends on several requirements.
A person generally must be at least 18 years old and have qualifying Medicare Part D prescription drug coverage.
Clinical eligibility also depends on BMI and certain medical conditions.
CMS bases the BMI requirement on the beneficiary’s BMI when GLP-1 therapy was initiated.
That rule can be important for people who have already lost weight while taking medication.
For example, a person could have started treatment with a BMI that satisfied the program’s requirements and later have a lower BMI. The provider’s assessment uses the applicable starting point rather than simply looking at the person’s current BMI.
The program recognizes several clinical pathways.
BMI of 35 or Higher
People who began GLP-1 treatment with a BMI of at least 35 can meet one of the program’s clinical eligibility pathways without needing one of the additional conditions listed for lower BMI categories.
BMI of 30 or Higher
A person with a starting BMI of at least 30 may qualify when at least one additional qualifying condition is present.
These conditions include:
- Heart failure with preserved ejection fraction
- Uncontrolled hypertension
- Chronic kidney disease stage 3a or higher
BMI of 27 or Higher
A person who began treatment with a BMI of at least 27 may also qualify when one of the specified medical conditions applies.
These include:
- Prediabetes
- A previous heart attack
- A previous stroke
- Symptomatic peripheral artery disease
Meeting a BMI threshold alone does not automatically guarantee enrollment.
The beneficiary must satisfy the applicable Medicare, clinical and prescription requirements.
Which Medicare Coverage Types Qualify?
The Bridge is connected to Medicare prescription drug coverage, so beneficiaries need to pay close attention to their plan type.
Eligible coverage can include Medicare Advantage plans that provide prescription drug coverage and standalone Medicare Prescription Drug Plans.
Certain Special Needs Plans and qualifying employer or union group waiver plans can also participate under the applicable rules.
The Limited Income Newly Eligible Transition program is another eligible category.
However, not every Medicare health arrangement qualifies automatically.
Some Medicare plan types have different requirements or exclusions under the demonstration.
This makes checking the beneficiary’s actual prescription drug coverage important before a provider submits a Bridge request.
Having Medicare Part A or Part B alone does not establish eligibility.
Which GLP-1 Medications Are Included?
The Bridge does not cover every GLP-1 medication on the market.
The current program includes specific products and formulations.
Foundayo
Foundayo is included for qualifying beneficiaries when it is prescribed for the covered weight-management purpose and all program requirements are met.
Its inclusion reflects CMS’s current medication list and applicable coverage rules.
Wegovy
Wegovy is also included under the Bridge for qualifying weight-management use.
The program’s current medication rules include eligible Wegovy formulations, including injection and tablet options covered under the applicable requirements.
Zepbound
Zepbound is included through the KwikPen formulation under the current Bridge rules.
Beneficiaries should pay attention to the exact formulation prescribed.
The Bridge does not treat every Zepbound presentation as interchangeable for program purposes. The single-dose vial and single-dose pen formulations are not covered through the Bridge.
Medication lists can change during a federal demonstration, so patients and providers need to use the current program information when submitting prescriptions.
How Much Does the Program Cost?
The Bridge establishes a $50 copayment for a monthly supply for eligible beneficiaries.
Depending on the medication, a monthly supply generally represents 28 or 30 days.
The $50 amount is one of the most notable features of the program because it creates a standardized beneficiary payment for eligible prescriptions.
However, the payment follows different rules from regular Part D cost sharing.
The $50 Bridge copayment does not count toward the beneficiary’s Medicare Part D deductible.
It also does not count toward the annual Part D out-of-pocket limit.
The payment does not become part of the beneficiary’s TrOOP calculation.
This distinction can be important for people who track their annual Medicare prescription expenses.
The Medicare Prescription Payment Plan also cannot be used to spread the Bridge copayment over multiple months.
Similarly, Medicare Extra Help does not reduce the Bridge’s $50 copayment.
Does Every GLP-1 Prescription Cost $50?
No.
The $50 amount applies when an eligible prescription is processed through the Bridge and the beneficiary satisfies all applicable requirements.
It does not mean every Medicare beneficiary can obtain any GLP-1 medication for $50.
A person receiving a GLP-1 through normal Part D coverage follows the cost-sharing rules of that coverage.
The Bridge has its own eligibility and processing requirements.
The reason for the prescription also matters. A medication prescribed for a medical indication covered under regular Part D may need to go through the beneficiary’s existing prescription drug plan rather than the Bridge.
What Medical Uses Are Covered?
The Bridge is focused on reducing excess body weight or maintaining weight reduction.
The prescription must meet the program’s requirements for weight-management use.
Some GLP-1 medications have other FDA-approved indications that can receive Medicare Part D treatment under applicable rules.
CMS specifically identifies conditions such as type 2 diabetes and certain other covered medical uses as matters that may fall under regular Part D coverage instead of the Bridge.
This distinction helps prevent confusion between weight-management treatment and treatment for another qualifying medical condition.
The prescriber must identify the appropriate medical purpose when submitting the prescription and authorization information.
What About Heart Disease and Stroke?
Cardiovascular history can play a role in Bridge eligibility, but the reason for prescribing the medication remains important.
For some beneficiaries with a BMI of at least 27, a previous heart attack or stroke can satisfy one of the additional clinical requirements.
Symptomatic peripheral artery disease can also qualify under the applicable pathway.
However, the Bridge is not simply a cardiovascular treatment program.
If a GLP-1 is prescribed specifically for a cardiovascular indication covered through the beneficiary’s normal Part D benefit, the prescription may need to be processed through that regular coverage instead.
The distinction is based on the applicable indication and Medicare coverage rules.
How Prior Authorization Works
Prior authorization is required under the Bridge.
The process normally starts when an eligible provider writes a prescription for an included medication.
The pharmacy then submits the claim through the program’s designated processing system.
If additional authorization is necessary, the pharmacy sends a request to the prescriber.
CMS provides electronic and fax-based methods for submitting the required information.
One important administrative rule is that providers should not submit the authorization request before the pharmacy submits the associated claim.
Submitting information too early can produce a patient-not-found error.
Once the request is properly submitted, CMS says the authorization decision is communicated within 72 hours.
The beneficiary receives a written decision, while the provider receives the decision through the applicable electronic system or by fax.
How Long Does an Approval Last?
An approved Bridge authorization can remain effective through December 31, 2027, subject to the program’s eligibility rules.
Beneficiaries generally do not need a new authorization for every monthly refill once the prescription has been approved.
However, circumstances can require a new authorization.
Switching from one covered GLP-1 product to another may require another authorization.
Changes in eligibility can also affect continued access.
Patients should therefore avoid assuming that approval guarantees coverage regardless of future circumstances.
How Pharmacies Handle the Program
The Bridge uses a centralized processing structure for claims.
For 2026, CMS selected Humana as the central processor. The processor handles administrative functions connected with the demonstration, including claims processing and prior authorization.
Pharmacies do not need to individually enroll in the Bridge.
The system is designed so eligible prescriptions can move through the designated claims process when the beneficiary and medication meet the program’s requirements.
Patients should still confirm that their pharmacy can process the prescription correctly before expecting the $50 Bridge copayment.
The Bridge also does not permit manufacturer coupons or discount programs to be applied to Bridge claims.
Can Beneficiaries Get a 90-Day Supply?
No.
The Bridge is structured around monthly dispensing.
The program provides one monthly supply per fill.
A 60-day or 90-day prescription cannot simply be processed as a longer Bridge supply.
Partial fills below the required monthly supply also do not qualify under the standard Bridge rules.
This means beneficiaries should expect the medication to be handled on a monthly basis when using the demonstration.
What Happens If Someone Already Uses a GLP-1?
Previous GLP-1 use through Medicare can affect eligibility.
The Bridge is not intended to provide a second source of coverage for someone who is already receiving an eligible GLP-1 through the regular Part D benefit.
CMS uses Medicare data to determine whether beneficiaries have previously received qualifying GLP-1 medications through Part D.
For 2026, prior Part D use can prevent a beneficiary from using the Bridge for the applicable period.
This makes a person’s existing prescription history an important part of the eligibility process.
Patients should tell their providers about current and previous GLP-1 prescriptions before starting the authorization process.
What the 2027 Extension Means
CMS has extended the Bridge through December 31, 2027.
The extension provides more time for CMS to collect information about GLP-1 use among Medicare beneficiaries.
It also gives the agency additional time to evaluate the effects of increased access.
The Bridge is connected to the federal government’s broader work involving GLP-1 medications and Medicare policy, but the current program itself remains a distinct demonstration.
CMS has delayed the Medicare Part D portion of the BALANCE Model for calendar year 2027.
As a result, the Bridge will continue during 2027 rather than ending when that model was originally expected to affect Medicare Part D coverage.
The extension does not establish permanent Medicare coverage for weight-loss GLP-1 medications.
What Beneficiaries Should Check Before Requesting Coverage
A beneficiary considering the Bridge should verify several details before expecting a $50 prescription.
First, confirm that the Medicare plan provides qualifying Part D coverage.
Next, discuss the person’s BMI history and relevant medical conditions with the prescribing provider.
The provider should also confirm that the requested medication and formulation are included under the current Bridge rules.
The prescription’s medical purpose matters as well.
Finally, the beneficiary should complete the required prior authorization process when applicable.
A simple checklist includes:
- Medicare Part D eligibility
- Age requirement
- BMI at the beginning of GLP-1 treatment
- Qualifying medical condition, when required
- Eligible medication
- Eligible formulation
- Appropriate weight-management indication
- Prior authorization
- Pharmacy claim processing
Checking these points can help prevent delays and misunderstandings about coverage.
Medicare Bridge Program GLP1: What to Know Now
The Medicare Bridge program glp1 gives eligible Medicare beneficiaries a defined route to certain GLP-1 medications for weight management at a $50 monthly copayment.
The program is active and available nationwide.
However, eligibility is not automatic. Medicare coverage status, BMI, medical history, medication choice, prescription purpose and prior authorization all play a role.
The current program also has a firm timetable. CMS has extended the demonstration through December 31, 2027, giving the agency additional time to evaluate the program and collect information about GLP-1 utilization.
For beneficiaries, the most important step is to determine whether their individual circumstances meet the current requirements rather than relying on the general $50 price alone.
Frequently Asked Questions
Q: What is the Medicare GLP-1 Bridge?
A: It is a CMS demonstration that provides qualifying Medicare Part D beneficiaries with access to selected GLP-1 medications for weight management.
Q: When did the Medicare GLP-1 Bridge begin?
A: The program began July 1, 2026.
Q: How much is the monthly copayment?
A: Eligible beneficiaries pay $50 for a monthly supply processed through the Bridge.
Q: Does the $50 count toward the Part D out-of-pocket limit?
A: No. The Bridge payment operates separately from regular Part D cost sharing.
Q: Which medications are covered?
A: The current program includes Foundayo, Wegovy and the Zepbound KwikPen formulation when the applicable requirements are met.
Q: Can everyone with Medicare use the program?
A: No. Beneficiaries must meet the program’s Medicare, clinical and medication requirements.
Q: Does BMI determine eligibility?
A: BMI is an important eligibility factor. The applicable threshold depends on whether the beneficiary also has certain qualifying medical conditions.
Q: Does the program cover GLP-1 treatment for diabetes?
A: The Bridge is designed for qualifying weight-management treatment. GLP-1 treatment for indications covered by regular Medicare Part D follows the applicable Part D coverage rules.
Q: Is prior authorization required?
A: Yes. The Bridge uses a prior authorization process for eligible prescriptions.
Q: How quickly can a prior authorization decision be made?
A: CMS says decisions are communicated within 72 hours after the properly submitted request.
Q: Can the Bridge cover a 90-day prescription?
A: No. The program provides one monthly supply per fill rather than 60-day or 90-day fills.
Q: When does the Bridge currently end?
A: The current demonstration runs through December 31, 2027.
Q: Is the Bridge permanent Medicare coverage?
A: No. It is a federal demonstration with a current end date of December 31, 2027.
Stay informed about Medicare GLP-1 Bridge eligibility, costs and coverage rules as the program continues through 2027.